Abstract Background Deferoxamine (DFO) is one of the most commonly used chelation treatments for transfusional hemosiderosis. Pattern dystrophies constitute a distinct entity of retinal disorders that has been occasionally identified in association with deferoxamine. Case presentation We report two cases of bilateral macular pattern dystrophy in transfusion dependent patients undergoing chronic chelation therapy with deferoxamine due to thalassemias. Our patients were evaluated with multimodal imaging and the results are presented. Both patients had normal cone and rod responses in the full-field electroretinogram and continued the prescribed chelation therapy, after hematology consult. The patients were followed up every 3 months for 2 and...
Although blood transfusions are important for patients with hemoglobinopathies, chronic transfusions...
Juvenile hemochromatosis (JH) is a rare autosomal recessive disorder of iron metabolism, genetically...
About the 11–14% of patients with thalassemia major (TM) treated with deferasirox (DFO) develops ret...
PURPOSE: To describe macular lesions in patients with deferoxamine (DFO) retinopathy, and to follow ...
WOS: 000360662000025Thalassemias are a heterogeneous group of autosomal recessive diseases character...
PURPOSE:To describe and classify patterns of abnormal fundus autofluorescence (FAF) of patients with...
PURPOSE: Deferoxamine (DFO) is a chelating agent used widely for the treatment of transfusional hemo...
Purpose: To describe spectral domain optical coherence tomography features in two cases of early def...
Deferoxamine mesylate (DFO) is the most commonly used iron-chelating agent to treat transfusion-rela...
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the ...
A 29-year-old lady receiving repeated blood transfusions for β thalassemia since childhood, presente...
Purpose: To study the ocular manifestations in multiple transfused beta-thalassemia major patients ...
Objective: To determine the incidences of ocular toxicity and ocular findings, including structural ...
SUMMARY Three patients with rheumatoid disease were given the 'iron chelating ' drug desfe...
Transfusional hemosiderosis is a frequent complication in patients with transfusion dependent chroni...
Although blood transfusions are important for patients with hemoglobinopathies, chronic transfusions...
Juvenile hemochromatosis (JH) is a rare autosomal recessive disorder of iron metabolism, genetically...
About the 11–14% of patients with thalassemia major (TM) treated with deferasirox (DFO) develops ret...
PURPOSE: To describe macular lesions in patients with deferoxamine (DFO) retinopathy, and to follow ...
WOS: 000360662000025Thalassemias are a heterogeneous group of autosomal recessive diseases character...
PURPOSE:To describe and classify patterns of abnormal fundus autofluorescence (FAF) of patients with...
PURPOSE: Deferoxamine (DFO) is a chelating agent used widely for the treatment of transfusional hemo...
Purpose: To describe spectral domain optical coherence tomography features in two cases of early def...
Deferoxamine mesylate (DFO) is the most commonly used iron-chelating agent to treat transfusion-rela...
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the ...
A 29-year-old lady receiving repeated blood transfusions for β thalassemia since childhood, presente...
Purpose: To study the ocular manifestations in multiple transfused beta-thalassemia major patients ...
Objective: To determine the incidences of ocular toxicity and ocular findings, including structural ...
SUMMARY Three patients with rheumatoid disease were given the 'iron chelating ' drug desfe...
Transfusional hemosiderosis is a frequent complication in patients with transfusion dependent chroni...
Although blood transfusions are important for patients with hemoglobinopathies, chronic transfusions...
Juvenile hemochromatosis (JH) is a rare autosomal recessive disorder of iron metabolism, genetically...
About the 11–14% of patients with thalassemia major (TM) treated with deferasirox (DFO) develops ret...